Novel diabetes drugs have recently been developed, and the mechanisms of these drugs are enhancing insulin secretion responding to postprandial hyperglycemia through GLP-1 signaling [22, 23] and inhibition of glucose absorption via SGLT2 [24, 25]. This evidence concerns the gene INS and Hyperglycemia.